Brigimadlin

Liposarcoma, a common subtype of soft tissue sarcoma, includes dedifferentiated liposarcoma (DDLPS) with high MDM2 amplification. Brigimadlin, an MDM2-p53 antagonist, showed stable disease in 75% of patients in a phase 1a/1b study. A phase 2/3 Brightline-1 trial compares brigimadlin to doxorubicin in advanced DDLPS, aiming to identify optimal dosing and assess progression-free survival.

Boehringer Ingelheim reported 7.4% net sales growth in H1 2024, driven by high demand for its medications. The company achieved milestones in CRM health and oncology, with promising Phase II results for survodutide in MASH and Phase Ia/Ib trial data for Zongertinib. Boehringer plans up to 25 new Human Pharma launches by 2030 and 20 in Animal Health by 2026.

Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, and cardiovascular diseases. It plans 10 new Phase II and III trials soon, with promising candidates like Brigimadlin and zongertinib. Despite slow sales of Cyltezo, 2023 saw a 9.7% sales increase, driven by Jardiance and Ofev.